You are missing some Flash content that should appear here! Perhaps your browser cannot display it, or maybe it did not initialise correctly.
You are missing some Flash content that should appear here! Perhaps your browser cannot display it, or maybe it did not initialise correctly.
Home
Profile
R&D
Product Pipeline
Investors
Partners
News & Events
Search this site:
Home
› Site map
Site map
Primary links
Home
Profile
People
Executive committee
Founders
Scientific comittee
Supervisory board
History
Key numbers
Strategy and market potential
R&D
Scientific base of our Company
Drug development and competencies
R&D organization
Product Pipeline
IPH2102, anti-KIR mAb licensed to Bristol-Myers Squibb
IPH2201 (NN8765), anti-NKG2A mAb licensed to Novo Nordisk A/S
Proprietary programs
IPH41, cytotoxic antibody
IPH33, immunomodulating antibody
Investors
Share information
Share Price
Shareholders
Analyst coverage
Financial Calendar for 2012
Documentation Center
Financial reports
Newsletter to shareholders
Presentations
OSEO label
Regulated information in France
Financial reports
Internal control and governance reports
Fees received by Statutory Auditors
Number of shares and voting rights
Share repurchase: liquidity agreement
Prospectus related to public offerings
Documentation related to the December 2009 capital increase
Documentation related to the IPO (October 2006)
General Shareholders' Meeting preparatory documents
Annual general meeting documents 2010
Annual general meeting documents 2009
Annual general meeting documents 2008
Annual general meeting documents 2007
Annual list of information published or made public
Declaration by the Management Board and the Supervisory Board members
Articles of association
Corporate governance
Investor relations
Partners
News & Events
All press releases
In the Media
Secondary links
Contact
Location
Site map
Legal Info
job opportunities